罗格列酮对乙烯雌酚诱发的大鼠泌乳素腺瘤治疗作用的初步研究

目的采用乙烯雌酚（DES）诱发方法建立垂体催乳素（PRL）腺瘤模型，研究罗格列酮对PRL腺瘤的影响。方法首先将20只雌性Wistar大鼠分为皮下植入含DES硅胶管的DES组（A0组）及皮下植入空白硅胶管的空白对照组（B0组）。8周后处死所有大鼠，观察并比较两组大鼠的血清PRL水平、垂体质量、垂体中PRL蛋白分布及细胞周期素D1（Cyclin D1）的表达。然后取雌性Wistar大鼠40只．皮下均植入含DES的硅胶管．8周时分为空白对照组（A组），溴隐亭组（B组）、大剂量罗格列酮组（C组）、中剂量岁格列酮组（D组）、小剂量罗格列酮组（E组）。药物干预4周后分别处死大鼠．观察各组大鼠血清PRL水平、垂体质量、垂体中PRL蛋白分布及Cyclin D1的表达，结果雌性Wistar大鼠皮下埋植含DES的硅胶管8周后均能形成垂体PRL腺瘤。在B、C组．药物干预后血清PRL值、垂体质量、垂体中PRL蛋门分布均较A、D、E、A0组降低，差异有统计学意义（P〈0．05）：但B、C组间差异无统计学意义（P〉0．05），C组垂体中CyclinD1表达较A、B组及A0组降低，差异有统计学意义（P〈0．05）。结论罗格列刚对DES诱发的大鼠PRL腺瘤有治疗作用。

Effect of rosiglitazone on diethylstilbestrol-induced rat prolactinoma

Objective To establish a prolactinoma model induced by diethylstilbestrol(DES) in female Wistar rats,and study the effects of rosiglitazone on rat prolactinoma.Methods Firstly,twenty female Wistar rats were divided into 2 groups at random.Each rat in DES group(A0) was subcutaneously implanted with DES encapsulated in silastic tube.Each rat in control group(B0) was implanted with blank silastic tube.After 8 weeks,all the animals were sacrificed for weight of the pituitary gland,serum prolactin(PRL) level,PRL-immunoreactive cell count and cyclin D1 expression in prolactinoma.Secondly,forty female Wistar rats were subcutaneously implanted with DES encapsulated in silastic tube.After 8 weeks,rats in DES group were divided into control group(A),bromocriptine group(B),high dose rosiglitazone group(C),middle dose rosiglitazone group(D),and low dose rosiglitazone group(E).After 4 weeks of treatment,all the animals were sacrificed for weight of the pituitary gland,serum PRL level,PRL-immunoreactive cell count and cyclin D1 expression in prolactinoma.Results Subcutaneous DES implantation is capable of forming prolactinoma in female Wistar rats.After 8 weeks,the serum PRL levels,weight of pituitary gland,PRL-immunoreactive cell count in groups B and C were significantly lower than those in groups A,D,E or A0(P<0.05).All the parameters showed no difference between group B and C(P>0.05).The expression of cyclin D1 in group C was significantly lower than those of groups A,B or A0(P<0.05).Conclusion Rosiglitazone has therapeutic effect against DES-induced prolactinoma in rats.